Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1992-4-28
|
| pubmed:abstractText |
The introduction of 99mTc-labeled anti-granulocyte antibodies seemed to provide advantages in comparison with formerly used in vitro methods to label autologous white blood cells for inflammation imaging. For this reason, we have undertaken a study to evaluate the clinical significance of this method. Thirty unselected patients with suspected bone infections were studied prospectively using the monoclonal 99mTc-labeled anti-granulocyte antibody. Twenty patients were referred with suspected infections of the peripheral bones (Group I), as well as 10 patients with suspected infections of the spine (Group II). Planar whole-body scans were performed 4 hr and 20 to 24 hr after administration of 500 MBq of the labeled antibody. Scans were considered positive for a bacterial (septic) infection when a focally increased antibody accumulation occurred. All scans were evaluated in blinded fashion by two experienced readers. Of the 20 studies from Group I patients, four false-positive scintigraphic findings were observed, and one false-negative, resulting in a specificity of only 64% and a sensitivity of 89%. In Group II (10 studies), five scans were true-negative, and five false-negative. For both groups, the specificity of the scintigraphic method was quite low (75%), and the sensitivity was also relatively low (57%). The results of this study demonstrate that in an unselected patient population in whom the diagnosis is not known, scintigraphy with 99mTc-anti-granulocyte antibodies is not a reliable method for detecting septic inflammatory lesions: In addition, use of this method excludes septic lesions with only a moderate likelihood (83% negative predictive value).
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0161-5505
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
33
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
526-31
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:1552336-Adolescent,
pubmed-meshheading:1552336-Adult,
pubmed-meshheading:1552336-Aged,
pubmed-meshheading:1552336-Antibodies,
pubmed-meshheading:1552336-False Positive Reactions,
pubmed-meshheading:1552336-Female,
pubmed-meshheading:1552336-Granulocytes,
pubmed-meshheading:1552336-Humans,
pubmed-meshheading:1552336-Male,
pubmed-meshheading:1552336-Middle Aged,
pubmed-meshheading:1552336-Osteomyelitis,
pubmed-meshheading:1552336-Sensitivity and Specificity,
pubmed-meshheading:1552336-Technetium
|
| pubmed:year |
1992
|
| pubmed:articleTitle |
Technetium-99m-labeled anti-granulocyte antibodies in suspected bone infections.
|
| pubmed:affiliation |
Department of Nuclear Medicine, University of Bonn, Germany.
|
| pubmed:publicationType |
Journal Article
|